1.	AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2006-00055-18, NCT00415103
2.	Bevacizumab in Extensive Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
3.	Phase III Randomized Study of Sequential High-Dose Ifosfamide, Carboplatin, and Etoposide Phosphate Followed By Autologous Peripheral Blood Stem Cell or Bone Marrow Transplantation Versus Standard Ifosfamide, Carboplatin, and Etoposide in Patients With Limited or Extensive Stage Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 65 and under Sponsor: Other Protocol IDs: EBMT-RANDOM-ICE, EU-98001, NCI-V01-1645, NCT00011921
4.	Phase III Study of Neoadjuvant Chemotherapy in Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Blood Stem Cell Support Phase: Phase III Type: Treatment Status: Closed Age: Under 1 Sponsor: Other Protocol IDs: CCLG-NB-1999-03, EU-20597, NCT00417053
5.	Phase III Study of Combination Chemotherapy Comprising Carboplatin or Cisplatin, Etoposide Phosphate, and Ifosfamide and Radiotherapy in Patients With Intracranial Germ Cell Tumors Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CCLG-GC-1997-01, EU-20579, SIOP-CNS-GCT-96, NCT00293358
6.	Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: D0750018, NCT00660504
7.	Further Retrospect Clinical Study for FDA IND Exemption - Etoposide and Single Nucleotide Polymorphisms Phase: Phase III Type: Biomarker/Laboratory analysis Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: FWA00015357, NPI - 1831468511, NPI - 1023387701, NCI CTEP ID - MD153, NCI Investigator ID - 49256, NCT01064466
8.	Phase I/II Study of Topotecan as a Component of Multicourse High Dose Chemotherapy with Peripheral Blood Stem Cell Support in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CPMC-IRB-7866, NCI-G97-1327, NCT00003064
9.	Phase I/II Study of Intensive Dose Melphalan, Topotecan, and Etoposide Phosphate Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma (Summary Last Modified 05/2002) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 15 to 69 Sponsor: NCI Protocol IDs: MCC-11752, MCC-IRB-4983, NCI-G00-1749, NCT00005792
10.	A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 1 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: CLO21800205, NCT00315705
11.	Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 1 to 25 Sponsor: NCI, Other Protocol IDs: 07053, P30CA033572, CHNMC-07053, CA180 121, CDR0000617760, NCT00788125
12.	GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PR-CS010, NCT00776802
13.	A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060534, NCT00791154
14.	Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CWRU4196, P30CA043703, BMS-CRWU-4196, NCI-G00-1854, NCT00006260
15.	Phase II Pilot Study of Intensification Comprising High-Dose Thiotepa and Cyclophosphamide With Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) and Sargramostim (GM-CSF) Followed By High-dose Carboplatin, Etoposide, and Melphalan With Second PBSCT, GM-CSF, and Isotretinoin After Induction Therapy in Children With Newly Diagnosed High-Risk Neuroblastoma Phase: Phase II Type: Treatment Status: Completed Age: 30 and under at original diagnosis Sponsor: NCI Protocol IDs: COG-ANBL00P1, NCT00017368
16.	Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000276590, U10CA021115, ECOG-5501, E5501, NCT00057837
17.	Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: Other Protocol IDs: CNS 0294, NCT00179920
18.	Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: INST 1003C, NCT00250718
19.	Phase II Study for Patients With Relapsed Primary Central Nervous System Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: OSU-0329, NCT00261651
20.	Phase II Randomized Study of Maintenance Therapy Versus Consolidation Therapy With Bortezomib After Aggressive Chemoimmunotherapy and Autologous Stem Cell Transplantation in Patients With Previously Untreated Mantle Cell Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 70 Sponsor: NCI Protocol IDs: CALGB-50403, NCT00310037
21.	Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 64 and under Sponsor: Other Protocol IDs: AMC 2005-276, NCT00336843
22.	A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CG53135-CLN-12, NCT00323518
23.	Dose Augmented Rituximab and Ice for Patients With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 to 72 Sponsor: Other Protocol IDs: 03-075, NCT00588094
24.	Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 1 to 21 Sponsor: NCI Protocol IDs: NCI-2009-00323, U10CA098543, CDR0000594224, AAML07P1, COG-AAML07P1, NCT00666588
25.	A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Phase: Phase II Type: Treatment Status: Closed Age: 30 and under Sponsor: Other Protocol IDs: OS2008, GENENTECH PHARM, NCT00667342